Advaxis

ADXS NASDAQ
2.250
-0.040
-1.75%
Opening 09:30 06/20 EDT
Open
2.340
Prev Close
2.290
High
2.340
Low
2.250
Volume
6.21K
Avg Vol (3M)
536.61K
52 Week High
26.55
52 Week Low
2.080
% Turnover
0.08%
Market Cap
18.05M
1D
5D
1M
3M
1Y
5Y

Company Profile

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
MORE >

Recently

Name
Price
%Change